Germany’s CureVac COVID-19 vaccine flops in clinical trial
June 18 2021, 08:00
Preliminary data behind German biopharmaceutical company CureVac's COVID-19 vaccine candidate revealed a disappointing 47% efficacy against COVID-19 disease of any severity, and failed to meet statistical success criteria in a late-stage trial, sending stocks tanking.
Preliminary data behind German biopharmaceutical company CureVac's COVID-19 vaccine candidate revealed a disappointing 47% efficacy against COVID-19 disease of any severity, and failed to meet statistical success criteria in a late-stage trial, sending stocks tanking.
Source:
FOX News